SEC Form 4 · accession 0001179110-18-014134
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alison A. Armour
Officer — Chief Medical Officer
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 17, 2018 | M | 35,000 | $5.16 | A | 136,040 | D | |
| Common Stock | Dec 17, 2018 | M | 14,212 | $3.18 | A | 150,252 | D | |
| Common Stock | Dec 17, 2018 | M | 1 | $2.16 | A | 150,253 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $5.16 | Dec 17, 2018 | M | 35,000 | D | — | Jul 31, 2025 | Common Stock | 35,000 | 25,000 | D |
| Stock option (right to buy)F2 | $3.18 | Dec 17, 2018 | M | 14,212 | D | — | Feb 4, 2026 | Common Stock | 14,212 | 45,788 | D |
| Stock option (right to buy)F3 | $2.16 | Dec 17, 2018 | M | 1 | D | — | Feb 2, 2027 | Common Stock | 1 | 39,999 | D |
Explanation of responses
- F1Shares subject to this option vest 1/4 annually over a period of four years beginning July 31, 2016.
- F2Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017.
- F3Shares subject to this option vest 1/4 annually over a period of four years beginning February 2, 2018.